Borrower record · Q2 2026
PCI Pharma Services
As filed by 4 BDCs · period end 30 June 2026Filers label it: Health Care Equipment & Services (3)2 name variants under review
Four lenders report $160.8m of PCI Pharma Services at Q2 2026, marked at 98.6 cents. The filed maturities run to October 2032.
- Filed fair value
- $160.8m
- 12 funded positions
- Reporting lenders
- 4
- across 16 filed positions
- Aggregate mark
- 98.6c
- covers 56% of positions with a filed cost
- Median spread
- 500bp
- over SOFR, 12 tranches
- Maturities to
- 2032
- earliest October 2032
- Periods on record
- 5
- first filed Q2 2025
How this total is counted
- Every figure above is the sum of 12 funded positions filed by 4 BDCs, each one cited below.
- Counted from the Q2 2026 filings imported for this build, the latest of them filed 20 August 2026. A schedule filed after that date is not in these figures and will appear when the property is rebuilt.
- 4 filed positions carry no positive fair value — unfunded or written off — and are outside every figure above.
- 2 filed name variants are under review against this borrower. Until they are resolved, anything filed under those names is counted nowhere on this page.
Pricing as filed
12 floating tranches · SOFR500bp on all 12 floating tranches — every filer reports the same spread.
9 tranches carry an index floor of 0.8%.
Rate structure
Floating, on all 12 positions whose interest type a filer disclosed.
Maturity profile
all 12 funded positions dated6.3 years to maturity, weighted by fair value across the 12 dated positions.
Credit flags
No lender reports this borrower on non-accrual, and no filed tranche pays in kind.
Not in the filings
- No sector. 3 filers file the same industry string, shown above as filed, but it has not cleared the corroboration test.
- No period-by-period totals across the 5 periods on record. A single filer is separable somewhere in that history — at a period only one of them reported, or in the difference between two — so the series would give up that filer's position.
- No filed seniority on any of the 12 funded positions.
- No filed cost on 44% of positions, which the aggregate mark therefore excludes.
Sign up for free
Who holds it, and where they mark it.
4 lenders hold the same credit and mark it differently. Behind the gate, one row each — for this borrower and for every other one on this site, free and with no limit on how many you read.
- The spread between the highest and lowest lender mark
- Quarter-on-quarter movement across 5 periods
- Peer comparison against borrowers with the same lenders
- The 10-Q or 10-K behind every row, by accession number
Every filing behind this page
4 filers · Q2 2026| Filer | CIK | Form | Period | Filed | Accession |
|---|---|---|---|---|---|
| FS KKR Capital Corp (FSK) | 0001422183 | 10-Q | 2026-06-30 | 2026-08-06 | 0001628280-26-053783 |
| KKR Enhanced US Direct Lending Fund-L Inc. | 0002012839 | 10-Q | 2026-06-30 | 2026-08-13 | 0001628280-26-056657 |
| KKR FS Income Trust | 0001930679 | 10-Q | 2026-06-30 | 2026-08-12 | 0001628280-26-056131 |
| KKR FS Income Trust Select | 0001975736 | 10-Q | 2026-06-30 | 2026-08-12 | 0001628280-26-056136 |
Related borrowers
Same lenders